It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical Information Request
Medical Information Request

Home > Other safety-related topics > Injection Reactions

Injection Reactions

 
Injection-Related Reactions
INjection-related-reaction

 

Injection-Related Reactions With Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS l and ll Trials

Pingili R, et al. CMSC 2020. DXT61.

 

 

  • Injection systemic and local-site reactions were predominantly reported with the first injection and reduced with subsequent injections
  • Most of the injection reactions (99.8%) were both mild to moderate in severity and mostly non-serious in nature with very low withdrawal rate (0.1%)
  • Injection reactions recovered with symptomatic treatment even in the absence of premedication

 

Download PDF
line break


Risk of injection-related reactions was evaluated from ALITHIOS study for up to 4 years and from the post marketing experience. Please see below for additional details

Additional information

IRR_1
Download Poster